<DOC>
	<DOCNO>NCT00864565</DOCNO>
	<brief_summary>To compare rate extent absorption fentanyl 25 μg/h transdermal system ( test ) Duragesic ( reference ) administrate 1 x 25 μg/h single transdermal system application .</brief_summary>
	<brief_title>A Relative Bioavailability Study Fentanyl 25 μg/h Transdermal System</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , 2-period , 2-sequence , crossover design . Official Title : Randomized , 2-way crossover , bioequivalence study Fentanyl 25 μg/h transdermal system Duragesic 25 μg/h transdermal system administrate 1 x 25 μg/h single application healthy subject Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Subjects females and/or male , smoker and/or nonsmoker , 18 55 year age . Subject capable consent . Female subject postmenopausal surgically sterilize . 1 . Postmenopausal status define absence menses past 12 month hysterectomy bilateral oophorectomy least 6 month ago . 2 . Sterile status define hysterectomy , bilateral oophorectomy tubal ligation least 6 month ago . Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical subinvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HlV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 100 140 mmHg , diastolic blood pressure low 60 90 mmHg ; heart rate less 60 100 bpm ) screening . Subjects BMI &gt; 30.0 . History significant alcohol abuse within six month screen visit indication regular use fourteen unit alcohol per week ( 1 Unit ≈ 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History abuse dependency use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within I year screen visit . History allergic reaction fentanyl , naloxone adhesive . History allergic reaction heparin . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO .inhibitors , neuroleptic , verapamil , quinidine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . History presence clinically significant liver kidney disease condition know interfere absorption , distribution , metabolism excretion drug . Any history presence clinically significant neurological . endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Smoking 25 cigarette per day . Any food allergy , intolerance , restriction special diet , opinion medical subinvestigator , contraindicate subject 's participation study . Subjects depot injection implant drug 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : 1.less 300 mL whole blood within 30 day 2.300 mL 500 mL whole blood within 45 day 3.more 500 mL whole blood within 56 day . Subjects consume food beverage contain grapefruit ( e.g . fresh , can , frozen ) within 7 day prior administration study medication . Subjects history presence asthma . chronic obstructive pulmonary disease pulmonary condition may predispose hypoventilation . Subjects history presence bradyarrythmias . Additional criterion female : Breastfeeding subject . Positive urine pregnancy test screening ( performed female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Fentanyl</keyword>
	<keyword>Healthy subject</keyword>
</DOC>